People: Response Genetics Inc (RGDX.W)
RGDX.W on CBOE When Trading NASDAQ Global Select Market
1.30USD
26 Mar 2013
1.30USD
26 Mar 2013
Price Change (% chg)
$0.05 (+4.00%)
$0.05 (+4.00%)
Prev Close
$1.25
$1.25
Open
$1.30
$1.30
Day's High
$1.30
$1.30
Day's Low
$1.30
$1.30
Volume
100
100
Avg. Vol
8
8
52-wk High
$1.98
$1.98
52-wk Low
$0.99
$0.99
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Thomas Bologna |
64 | 2011 | Chairman of the Board, Chief Executive Officer |
Kevin Harris |
43 | 2012 | Interim Chief Financial Officer |
Stephanie Astrow |
50 | 2012 | Vice President - Research & Development |
Kirk Calhoun |
68 | 2011 | Lead Independent Director |
Michael Serruya |
48 | 2000 | Director |
Michael Metzger |
41 | 2010 | Independent Director |
Gary Nusbaum |
45 | 2007 | Independent Director |
Richard van den Broek |
46 | 2010 | Independent Director |
David Wurzer |
53 | 2010 | Independent Director |
Peter Rahmer |
IR Contact Officer |
Biographies
| Name | Description |
|---|---|
Thomas Bologna |
Mr. Thomas A. Bologna serves as Chairman of the Board, Chief Executive Officer of Response Genetics Inc., since December 21, 2011. From April 2006 until his appointment as the Company’s Chief Executive Officer, Mr. Bologna served as President and Chief Executive Officer of Orchid Cellmark, Inc., a public corporation that provides DNA identity testing services. From 2004 to 2005, Mr. Bologna was Chief Executive Officer, President, and a director of Quorex Pharmaceuticals, Inc., a pre-clinical stage anti-infective company. From 1997 to 2003, Mr. Bologna was Chief Executive Officer, President, and a director of Ostex International, Inc., which developed, manufactured, and marketed products for the management of osteoporosis, and from 1999 to 2003 he was also chairman of the board of Ostex. From 1996 to 1997, Mr. Bologna was a principal at Healthcare Venture Associates, a consulting firm. From 1994 to 1996, Mr. Bologna was Chief Executive Officer, President, and a director of Scriptgen Pharmaceuticals, Inc., a biotechnology company with proprietary drug-screening technology that developed orally active drugs to regulate gene expression. From 1987 to 1994, Mr. Bologna was Chief Executive Officer, President, and a director of Gen-Probe Incorporated, a biotechnology company commercializing molecular diagnostics products and services, and from 1992 to 1994 he was also chairman of the board of Gen-Probe. Mr. Bologna’s prior experience also includes senior-level positions with Becton Dickinson & Company and Warner-Lambert Company. Mr. Bologna currently serves as chairman and director of Strategic Diagnostics Inc., a biotechnology company. Mr. Bologna also serves on the boards of Aperio Technologies, and Quotient Biodiagnostics. Mr. Bologna received an M.B.A. and a B.S. from New York University. |
Kevin Harris |
Mr. Kevin R. Harris has been appointed as Interim Chief Financial Officer Response Genetics, Inc., effective August 20, 2012. Mr. Harris previously served as Chief Financial Officer and a director of CyberDefender Corporation from 2009 until August 2012 (and as interim Chief Executive Officer from August 2011 until August 2012) and as Chief Operating Officer of Statmon Technologies Corp from 2004 to 2009. He began his career at KPMG Peat Marwick as a senior auditor. Mr. Harris’s other professional experience includes serving as Head of Production, Finance at PolyGram Television, Director of Corporate Financial Planning at Metro-Goldwyn-Mayer Studios and Senior Vice President of Finance at RKO Pictures. Mr. Harris earned a Bachelor of Science in Business Administration from California State University, San Bernardino and is a Certified Public Accountant in the State of California. |
Stephanie Astrow |
Dr. Stephanie H. Astrow, Ph.D., MBA, serves as Vice President - Research & Development of Response Genetics Inc., since March 2012. From December 2008 until she joined the Company, Dr. Astrow was Scientific Director for Oncology at Quest Diagnostics, the global provider of diagnostic testing. At Quest, Dr. Astrow played a key role in expanding business by introducing new assays and services, as well as coordinating development strategy for companion diagnostics with key pharmaceutical companies. Prior to joining Quest, Dr. Astrow served as Vice President and Director of Oncology at Pathway Diagnostics for 5 years. Dr. Astrow joined Pathway Diagnostics after spending over 5 years with IMPATH, Inc., where she held a variety of positions including Vice President, Scientific Director of IMPATH Predictive Oncology, a wholly-owned subsidiary. Dr. Astrow received a Bachelor of Arts in Biology and Medicine at Brown University, and her Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She also holds a Masters of Business Administration from Pepperdine University. |
Kirk Calhoun |
Mr. Kirk K. Calhoun has been appointed as Lead Independent Director of Response Genetics, Inc., effective December 2011. He has served as a member of the Board since May 2008. Mr. Calhoun joined Ernst & Young LLP, a public accounting firm, in 1965 and served as a partner of the firm from 1975 until his retirement in 2002. Mr. Calhoun is a Certified Public Accountant (non-practicing) with a background in auditing and accounting. He has served on the boards and audit committees of five public companies in the pharmaceutical industry up until the dates of their respective sales, including Abraxis Bioscience, Inc., Myogen, Inc., Aspreva Pharmaceuticals Company, Replidyne, Inc. and Adams Respiratory Therapeutics, Inc. Mr. Calhoun received a B.S. in Accounting from the University of Southern California. |
Michael Serruya |
Mr. Michael Serruya is Director of Response Genetics, Inc., since March 2000. Since February 2000, Mr. Serruya has been Chairman of Yogen Fruz World Wide Incorporated, a consumer products company and from 1995 to February 2000 he was President, Chief Executive Officer and Chairman of Yogen Fruz. He is currently on the board of directors of Jamba, Inc. (NASDAQ: JMBA), the holding company of Jamba Juice Company, which is a restaurant retailer of food and beverage offerings and owns and franchises Jamba Juice stores. Mr. Serruya was also a member of the Ontario Jobs and Investment Board, an organization headed up by the Ontario Provincial Government. Mr. Serruya was previously the President and Chief Executive Officer of CoolBrands International Inc. (TSE:COB.A), a company which manufactured and marketed frozen novelties, frozen yogurt, ice cream and sorbet products. Mr. Serruya is currently on the board of directors of Swisher Hygiene Inc. (NASDAQ: SWSH). Mr. Serruya attended Ryerson Polytechnical Institute. |
Michael Metzger |
Mr. Michael A. Metzger is Independent Director of Response Genetics, Inc., since 2010. He is Executive Vice President and Chief Operating Officer at Mersana Therapeutics, a biopharmaceutical company focused on pharmaceutical development, a position he has held since April 2011. Prior to joining Mersana, since 2006, he held senior positions within Business Development and led Mergers and Acquisitions at Forest Laboratories, Inc., a company focused on pharmaceutical development. Prior to 2006, Mr. Metzger was Vice President Corporate Development at Onconova Therapeutics, Inc., a clinical stage biopharmaceutical company focused on novel discovery and development of oncology compounds, from 2001 until 2006. Mr. Metzger was Managing Director at Mesa Partners, Inc., from 1997 to 2001. In addition, Mr. Metzger has served as a director of various life sciences companies. Mr. Metzger holds a B.A. from George Washington University and an M.B.A. from the New York University Stern School of Business. |
Gary Nusbaum |
Mr. Gary D. Nusbaum is Independent Director of Response Genetics, Inc., since August 2007. From 1989 until 2002, Mr. Nusbaum was at the private equity firm Warburg Pincus, where he was a Managing Director, and from 2003 until 2005, Mr. Nusbaum served as a Managing Director at Aetos Capital, an asset management firm. At Aetos Capital, Mr. Nusbaum was the firm’s Chief Financial Officer, and also headed its private equity business. From 2006 until 2010, Mr. Nusbaum was a Managing Director at Palladium Equity Partners, LLC, a private investment firm. Mr. Nusbaum received both his B.S. in Economics and M.B.A. from The Wharton School of the University of Pennsylvania. He has served as a board member of several public and private companies. |
Richard van den Broek |
Mr. Richard A. van den Broek is Independent Director of Response Genetics, Inc., since December 2010. He has served as the Managing Partner of HSMR Advisors, LLC, an investment fund focused on the biotechnology industry since 2004. Mr. Van den Broek, also spent ten years as a sell-side analyst covering the biotechnology industry, first at Oppenheimer, then Merrill Lynch and finally as Managing Director at Hambrecht & Quist. Mr. Van den Broek serves on the board of directors of Strategic Diagnostic Inc. and is a member of its audit committee. Mr. Van den Broek also serves as a director of Pharmaxis Ltd and CogState (both in Australia) and Pharmacyclics, Inc. and is a member of the Pharmacyclics’ audit committee. |
David Wurzer |
Mr. David M. Wurzer, CPA, is Independent Director of Response Genetics, Inc., since December 2010. He has served as Managing Director, Investments at Connecticut Innovations (“CI”), a quasi-public authority responsible for technology investing and innovation development since November 2009, where he is responsible for sourcing and analyzing investment opportunities. Prior to joining CI, Mr. Wurzer was a consultant from January 2008 through November 2009 and served as Executive Vice President, Treasurer and Chief Financial Officer of CuraGen Corporation of Branford, Connecticut, from September 1997 through December 2007. From February 1994 until September 1997, Mr. Wurzer served as the Senior Vice President, Treasurer and Chief Financial Officer at Value Health, Inc. Mr. Wurzer is currently a member of the board of directors of Strategic Diagnostics Inc. since February 2010 and of DUSA Pharmaceuticals Inc. since July 2010. Mr. Wurzer is currently a member of the board of directors of Axerion Therapeutics, Inc., CyVek, Inc., Post-N-Track Corporation, Thetis Pharmaceuticals, LLC, and NovaTract Surgical, LLC, which are privately held. Mr. Wurzer previously served on the 454 Life Sciences board of directors from June 2000 through May 2007. |
Peter Rahmer |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Thomas Bologna |
885,900 |
Kevin Harris |
-- |
Stephanie Astrow |
-- |
Kirk Calhoun |
-- |
Michael Serruya |
-- |
Michael Metzger |
-- |
Gary Nusbaum |
-- |
Richard van den Broek |
-- |
David Wurzer |
-- |
Peter Rahmer |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Thomas Bologna |
0 | 0 |
Kevin Harris |
0 | 0 |
Stephanie Astrow |
0 | 0 |
Kirk Calhoun |
0 | 0 |
Michael Serruya |
0 | 0 |
Michael Metzger |
0 | 0 |
Gary Nusbaum |
0 | 0 |
Richard van den Broek |
0 | 0 |
David Wurzer |
0 | 0 |
Peter Rahmer |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
AUSTIN W MARXE ET AL |
41,937 | $1.19 |
AUSTIN W MARXE ET AL |
421,341 | $1.00 |
BRIDGER MANAGEMENT L L C |
3,000,000 | $1.10 |
LANSDOWNE PARTNERS L P |
2,500 | $0.90 |
LANSDOWNE PARTNERS L P |
4,000 | $1.30 |
LANSDOWNE PARTNERS L P |
2,947 | $1.36 |
LANSDOWNE PARTNERS L P |
37,028 | $1.25 |
LANSDOWNE PARTNERS L P |
50,000 | $1.41 |
LANSDOWNE PARTNERS L P |
600 | $1.50 |
LANSDOWNE PARTNERS L P |
3,440 | $1.34 |
AUSTIN W MARXE ET AL |
6,800 | $1.92 |
AUSTIN W MARXE ET AL |
5,000 | $1.65 |
BECKER DRAPKIN MANAGEMENT L P |
100,000 | $1.60 |
AUSTIN W MARXE ET AL |
9,000 | $1.72 |
MARXE AUSTIN W ET AL |
300 | $1.75 |
MARXE AUSTIN W ET AL |
10,900 | $1.75 |
MARXE AUSTIN W ET AL |
48,300 | $1.52 |
MARXE AUSTIN W ET AL |
100,000 | $1.50 |
AUSTIN W MARXE ET AL |
300,000 | $1.90 |
BECKER DRAPKIN MANAGEMENT L P |
100,000 | $1.95 |
MARXE AUSTIN W ET AL |
2,811 | $1.26 |
VAN DEN BROEK RICHARD A |
100,000 | $1.50 |
BOLOGNA THOMAS A |
100,000 | $1.50 |
CALHOUN KIRK K |
10,000 | $1.50 |
SERRUYA MICHAEL |
1,000 | $1.50 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
